We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Adcom to Discuss Accelerated Approval of Fluad Flu Vaccine
FDA Adcom to Discuss Accelerated Approval of Fluad Flu Vaccine
The FDA’s Vaccines and Related Biological Products Advisory Committee will meet today to discuss the safety and immunogenicity of CSL’s influenza vaccine Fluad to determine if it should be approved through an accelerated approval pathway. The vaccine is proposed for use in people 65 and older as treatment against influenza types A and B.